| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 860.50 | 7.9% | 0.5% |
| Total Income | 860.50 | 7.9% | 0.5% |
| Expenditure | 912.30 | 16.1% | 14.6% |
| PBT | -71.80 | 14460.0% | 229.8% |
| Net Profit | -59.60 | 884.2% | 245.7% |
| OPM | -6.02% | 7.51pp | 13.90pp |
| NPM | -6.93% | 7.88pp | 11.66pp |
| EPS | -0.41 | 920.0% | 251.8% |
Bruker Reports Q3 2025 Revenue of $860.5M, Down 0.5% YOY
04 May 2026 · 4 May, 8:18 am
Summary
Bruker Corporation announced its Q3 2025 financial results, with revenues of $860.5 million, a slight decrease of 0.5% compared to the same period last year. The company's organic revenue decreased by 4.5% year-over-year. GAAP operating loss was $51.8 million, while non-GAAP operating income was $105.9 million. Bruker updated its FY2025 revenue guidance to $3.41 to $3.44 billion and non-GAAP EPS guidance to $1.85 to $1.90.
Key Highlights
- 1
Bruker's Q3 2025 revenues reached $860.5 million, a decrease of 0.5% year-over-year.
- 2
Organic revenue decreased by 4.5% year-over-year in Q3 2025.
- 3
The company reported a GAAP diluted loss per share of $(0.41) for Q3 2025, while non-GAAP diluted EPS was $0.45.
- 4
Bruker Scientific Instruments (BSI) revenues were $787.9 million in Q3 2025, down 1.5% year-over-year.
- 5
Bruker Energy & Supercon Technologies (BEST) revenues increased by 7.4% year-over-year to $73.8 million in Q3 2025.
- 6
The company updated its FY2025 revenue guidance to $3.41 to $3.44 billion, representing a 1-2% year-over-year growth.
- 7
Bruker now expects FY 2025 non-GAAP EPS to be in the range of $1.85 to $1.90.
Management Comments
Frank H. Laukien
In the third quarter, we were encouraged by our mid-single digit percentage organic bookings growth year-over-year, with a Scientific Instruments segment book-to-bill ratio greater than 1.0. For the first time this year, we saw strength in bookings in the academic/government market segment, as well as improving biopharma and applied markets orders. Notably, our innovative spatial biology, proteomics and multiomics solutions launched at AGBT and ASMS are being well received by our biopharma and academic customers and enhance our leadership in enabling tools for drug discovery and disease biology research in the post-genomic era. As forecasted, our third quarter revenues and earnings were down year-over-year, primarily due to weaker academic and research instruments demand in the first half of 2025. However, our Q3-25 non-GAAP financial performance was better than expected and represents a meaningful sequential step-up from Q2-25. Nonetheless, due to previous market weakness and EPS dilution from higher share count, we are lowering our FY2025 guidance. For FY2026, our major cost-savings initiatives are progressing well towards the high end of our $100 to $120 million cost-down targets and are expected to deliver significant operating margin expansion and EPS growth in 2026.
Informational and educational content only. Not investment advice.